Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC decreased its stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 26.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,978 shares of the company’s stock after selling 4,936 shares during the period. AQR Capital Management LLC’s holdings in Tenaya Therapeutics were worth $43,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Tenaya Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after purchasing an additional 403,472 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in shares of Tenaya Therapeutics in the 4th quarter worth approximately $228,000. American Century Companies Inc. lifted its holdings in shares of Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock worth $317,000 after purchasing an additional 22,146 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Tenaya Therapeutics by 42.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after acquiring an additional 30,446 shares in the last quarter. Finally, Integral Health Asset Management LLC raised its stake in Tenaya Therapeutics by 3.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after acquiring an additional 75,000 shares in the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

TNYA opened at $2.04 on Friday. Tenaya Therapeutics, Inc. has a one year low of $1.61 and a one year high of $7.01. The stock’s fifty day moving average is $2.27 and its 200-day moving average is $3.29. The company has a market capitalization of $160.18 million, a PE ratio of -1.24 and a beta of 2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, equities research analysts forecast that Tenaya Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TNYA has been the topic of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Friday. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.25.

Insider Transactions at Tenaya Therapeutics

In related news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the transaction, the chief executive officer now directly owns 188,331 shares in the company, valued at $544,276.59. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 19,539 shares of company stock valued at $56,468. Corporate insiders own 32.76% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.